The FDA approved Celltrion Healthcare’s Yuflyma (adalimumab-aaty), which is a high-concentration, citrate-free formulation.
The FDA has approved a ninth adalimumab (Humira) biosimilar. Yuflyma (adalimumab-aaty) from Celltrion Healthcare already has a launch date in July due to an agreement with AbbVie, the maker of the reference product.
Yuflyma is a high-concentration (100 mg/mL), citrate-free formulation, which means patients will inject a smaller volume and there will be less injection-site pain. Not all approved adalimumab biosimilars are the high-concentration/citrate-free formulations.
“Currently, more than 80% of patients treated with Humira in the United States rely on a high-concentration and citrate-free formulation of this medication,” Jonathan Kay, MD, professor, UMass Chan Medical School, said in a statement. “The availability of a high-concentration and citrate-free formulation adalimumab biosimilar provides an important treatment option for patients with inflammatory diseases who benefit from this effective therapy.”
The approval of Yuflyma is for 8 conditions: rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa.
Yuflyma will join a crowded field of adalimumab biosimilars, led by Amjevita, which has been on the market since January 31, 2023. There are 7 other adalimumab biosimilars expected to launch in July. The approval of multiple adalimumab biosimilars is expected to help bring down the cost of Humira, which is a top-selling drug and has had patent exclusivity for 20 years.
In February, Reuters reported that AbbVie expects sales of Humira to decline 37% in 2023 due to the competition of less expensive adalimumab biosimilars. Over those 20 years of exclusivity in the United States, Humira has brought in $200 billion in revenue for the company.
In addition to the 9 approved biosimilars, there is another awaiting approval: Alvotech’s AVT02, which has received 2 complete response letters due to deficiencies in the company’s manufacturing facility.
Celltrion is also seeking interchangeability designation for Yuflyma, which the company tentatively expects in the fourth quarter of 2024. Currently, there is only 1 interchangeable adalimumab biosimilar approved—Cyltezo from Boehringer Ingelheim. However, an interchangeability application for Abrilada from Pfizer is under review by the FDA, as is an application for AVT02.
Yuflyma’s approval is based on analytical, preclinical, and clinical studies demonstrating the agent is comparable to the reference product.
Kay was the lead investigator on a safety and efficacy study comparing Yuflyma with the reference product. The results were published in 2021 in Arthritis Research & Therapy.1 The randomized, double-blind phase 3 study reported on results to week 24. Patients with active rheumatoid arthritis were randomly assigned 1:1 to receive either Yuflyma or European Union–approved adalimumab.
The study found the ACR20 response rate (a 20% improvement in disease) at week 24 was 82.7% in both groups, and additional end points and overall safety were comparable between the groups.
In a switching study, Yuflyma had comparable efficacy, pharmacokinetics, safety, and immunogenicity compared with the reference product after 1 year of treatment that included switching from the reference to the biosimilar. The results were published in Rheumatology in 2022.2
References
1. Kay J, Jaworski J, Wojciechowski R, et al. Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study. Arthritis Res Ther. 2021;23(1):51. doi:10.1186/s13075-020-02394-7
2. Furst DE, Jaworski J, Wojciechowski R, et al. Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis. Rheumatology (Oxford). 2022;61(4):1385-1395. doi:10.1093/rheumatology/keab460
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Bleeds and Resource Use in Hemophilia B: Retrospective Observational Study
May 15th 2024This real-world US study describes individuals with hemophilia B who experience bleeds despite factor replacement therapy and quantifies the associated comorbidity and health care resource utilization burden.
Read More
A new study highlights significant disparity in reimbursement rates across states between hospitals and Medicare; the first patient to receive a genetically modified pig kidney has died; research examines outcomes of over 500 patients receiving medication abortion pills by mail.
Read More